Efficacy Comparison of Targeted Systemic Monotherapies Including Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: a Network Meta-Analysis. (2024). SKIN The Journal of Cutaneous Medicine, 8(1), s313. https://doi.org/10.25251/skin.8.supp.313